NCT04504526 2023-09-15
Value of Chemokine Receptor CXCR4 Imaging for Diagnosis and Prognostic Evaluation in Lymphoproliferative Diseases
First Affiliated Hospital of Fujian Medical University
Phase EARLY_PHASE1 Unknown
Clinical Trials
8 trialsNCT05519384 2022-11-28
Safety and Preliminary Efficacy of JK500 Cell Injection in Relapsed/Refractory Pediatric Acute Myeloid Leukemia
Institute of Hematology & Blood Diseases Hospital, China
Phase EARLY_PHASE1 Unknown
NCT05480501 2022-07-29
Clinical Trial to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) B-cell Acute Lymphoblastic Leukemia
Beijing Immunochina Medical Science & Technology Co., Ltd.
Phase EARLY_PHASE1 Unknown
NCT03795779 2021-05-19
CLL1-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies
iCell Gene Therapeutics
Phase EARLY_PHASE1 Unknown
NCT04439721 2021-01-06
γδT
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Phase EARLY_PHASE1 Unknown
NCT04156178 2019-11-12
CD20-CD19 Compound CAR (cCAR) T Cells for Patients With Relapsed /Refractory B Cell Malignancies
iCell Gene Therapeutics
Phase EARLY_PHASE1 Unknown
NCT04156256 2019-11-12
CD123-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies
iCell Gene Therapeutics
Phase EARLY_PHASE1 Unknown
NCT03910842 2019-09-06
Treatment of Children CD19+ Leukemia and Non-Hodgkin Lymphoma With CD19-TriCAR-T/SILK Cell Therapy
Timmune Biotech Inc.
Phase EARLY_PHASE1 Unknown